{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:17:02Z","timestamp":1778861822039,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biosci"],"DOI":"10.1007\/s12038-026-00593-z","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:27:59Z","timestamp":1778855279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypercholesterolemia-induced impairment in sorafenib functionality is overcome by avasimibe co-treatment"],"prefix":"10.1007","volume":"51","author":[{"given":"Dipti","family":"Athavale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshi","family":"Yaduvanshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firoz Khan","family":"Bhati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamananda Singh","family":"Mayengbam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tushar H","family":"More","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikanth","family":"Rapole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0397-5028","authenticated-orcid":false,"given":"Manoj Kumar","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"593_CR2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/onc.2012.113","volume":"32","author":"N Alikhani","year":"2013","unstructured":"Alikhani N, Ferguson RD and Novosyadlyy R 2013 Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene 32 961\u2013967","journal-title":"Oncogene"},{"key":"593_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40170-018-0187-2","volume":"6","author":"D Athavale","year":"2018","unstructured":"Athavale D, Chouhan S, Pandey V, et al. 2018 Hepatocellular carcinoma-associated hypercholesterolemia: Involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9). Cancer Metab. 6 16","journal-title":"Cancer Metab."},{"key":"593_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179558","volume":"12","author":"S Bandyopadhyay","year":"2017","unstructured":"Bandyopadhyay S, Li J, Traer E, et al. 2017 Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS One 12 e0179558","journal-title":"PLoS One"},{"key":"593_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2015.49","volume":"5","author":"S Beloribi-Djefaflia","year":"2016","unstructured":"Beloribi-Djefaflia S, Vasseur S and Guillaumond F 2016 Lipid metabolic reprogramming in cancer cells. Oncogenesis 5 e189","journal-title":"Oncogenesis"},{"key":"593_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2009.06.022","volume":"288","author":"J Bil","year":"2010","unstructured":"Bil J, Zapala L, Nowis D, et al. 2010 Statins potentiate cytostatic\/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett. 288 57\u201367","journal-title":"Cancer Lett."},{"key":"593_CR14","doi-asserted-by":"publisher","first-page":"27777","DOI":"10.1074\/jbc.M113.466656","volume":"288","author":"AG Cabodevilla","year":"2013","unstructured":"Cabodevilla AG, Sanchez-Caballero L, Nintou E, et al. 2013 Cell survival during complete nutrient deprivation depends on lipid droplet-fueled B-oxidation of fatty acids. J. Biol. Chem. 288 27777\u201327788","journal-title":"J. Biol. Chem."},{"key":"593_CR10","first-page":"413","volume":"20","author":"YK Chae","year":"2015","unstructured":"Chae YK, Yousaf M, Malecek MK, et al. 2015 Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit? Discov. Med. 20 413\u2013427","journal-title":"Discov. Med."},{"key":"593_CR8","first-page":"10","volume":"9","author":"KKW Chan","year":"2003","unstructured":"Chan KKW, Oza AM and Siu LL 2003 The statins as anticancer agents. Clin. Cancer Res. 9 10\u201319","journal-title":"Clin. Cancer Res."},{"key":"593_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/ajpendo.90926.2008","volume":"297","author":"T Chang","year":"2009","unstructured":"Chang T, Li B, Chang CCY, et al. 2009 Acyl-coenzyme A: Cholesterol acyltransferases. Am. J. Physiol. Endocrinol. Metab. 297 1\u201317","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"593_CR7","first-page":"1","volume":"7","author":"Y Chen","year":"2017","unstructured":"Chen Y, Liu YC, Sung YC, et al. 2017 Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci. Rep. 7 1\u201312","journal-title":"Sci. Rep."},{"key":"593_CR13","doi-asserted-by":"publisher","first-page":"23265","DOI":"10.18632\/oncotarget.15575","volume":"8","author":"Y Cheng","year":"2017","unstructured":"Cheng Y, Luo R, Zheng H, et al. 2017 Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma. Oncotarget 8 23265\u201323276","journal-title":"Oncotarget"},{"key":"593_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","volume":"38","author":"C Cheng","year":"2018","unstructured":"Cheng C, Geng F, Cheng X, et al. 2018 Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun. 38 27","journal-title":"Cancer Commun."},{"key":"593_CR9","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1038\/onc.2012.6","volume":"31","author":"JW Clendening","year":"2012","unstructured":"Clendening JW and Penn LZ 2012 Targeting tumor cell metabolism with statins. Oncogene 31 4967\u20134978","journal-title":"Oncogene"},{"key":"593_CR12","first-page":"153","volume":"10","author":"AM Crissien","year":"2014","unstructured":"Crissien AM and Frenette C 2014 Current management of hepatocellular carcinoma. Gastroenterol. Hepatol. 10 153\u2013161","journal-title":"Gastroenterol. Hepatol"},{"key":"593_CR16","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1158\/1078-0432.CCR-15-2973","volume":"22","author":"F Geng","year":"2016","unstructured":"Geng F, Cheng X, Wu X, et al. 2016 Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis. Clin. Cancer Res. 22 5337\u20135348","journal-title":"Clin. Cancer Res."},{"key":"593_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1083\/jcb.100.3.965","volume":"100","author":"P Greenspan","year":"1985","unstructured":"Greenspan P, Mayer EP and Fowler SD 1985 Nile Red: A selective fluorescent stain for intracellular lipid droplets. J. Cell Biol. 100 965\u2013973","journal-title":"J. Cell Biol."},{"key":"593_CR15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/j.1582-4934.2009.00697.x","volume":"13","author":"S Gupta","year":"2009","unstructured":"Gupta S, Kass GEN, Szegezdi E, et al. 2009 The mitochondrial death pathway: A promising therapeutic target in diseases. J. Cell. Mol. Med. 13 1004\u20131033","journal-title":"J. Cell. Mol. Med."},{"key":"593_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1194\/jlr.R067595","volume":"57","author":"J Han","year":"2016","unstructured":"Han J and Kaufman RJ 2016 The role of ER stress in lipid metabolism and lipotoxicity. J. Lipid Res. 57 1329\u20131338","journal-title":"J. Lipid Res."},{"key":"593_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1440-1746.1992.tb01026.x","volume":"7","author":"SJ Hwang","year":"1992","unstructured":"Hwang SJ, Lee SD, Chang CF, et al. 1992 Hypercholesterolaemia in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 7 491\u2013496","journal-title":"J. Gastroenterol. Hepatol."},{"key":"593_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0021-9150(00)00615-8","volume":"157","author":"W Insull","year":"2001","unstructured":"Insull W, Koren M, Davignon J, et al. 2001 Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis 157 137\u2013144","journal-title":"Atherosclerosis"},{"key":"593_CR21","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/bjc.2014.431","volume":"111","author":"P Jiang","year":"2014","unstructured":"Jiang P, Mukthavaram R, Chao Y, et al. 2014 In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br. J. Cancer 111 1562\u20131571","journal-title":"Br. J. Cancer"},{"key":"593_CR23","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1161\/CIRCRESAHA.116.305421","volume":"116","author":"J Karch","year":"2015","unstructured":"Karch J and Molkentin JD 2015 Regulated necrotic cell death: The passive aggressive side of bax and bak. Circ. Res. 116 1800\u20131809","journal-title":"Circ. Res."},{"key":"593_CR25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2957\/kanzo.59.587","volume":"59","author":"M Kudo","year":"2018","unstructured":"Kudo M 2018 Systemic therapy for hepatocellular carcinoma: Recent advances. Acta Hepatol. Jpn. 59 587\u2013603","journal-title":"Acta Hepatol. Jpn."},{"key":"593_CR24","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1158\/0008-5472.CAN-15-2613","volume":"76","author":"OF Kuzu","year":"2016","unstructured":"Kuzu OF, Noory MA and Robertson GP 2016 The role of cholesterol in cancer. Cancer Res. 76 2063\u20132070","journal-title":"Cancer Res."},{"key":"593_CR27","doi-asserted-by":"crossref","unstructured":"Li J, Gu, Lee SSY et al. 2016 Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene 35 6378\u20136388","DOI":"10.1038\/onc.2016.168"},{"key":"593_CR28","first-page":"1","volume":"13","author":"J Li","year":"2018","unstructured":"Li J, Qu X, Tian J, et al. 2018 Cholesterol esterification inhibition and gemcitabine synergistically suppresses pancreatic ductal adenocarcinoma proliferation. PLoS One 13 1\u201311","journal-title":"PLoS One"},{"key":"593_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41401-020-0404-8","volume":"42","author":"JY Liu","year":"2021","unstructured":"Liu JY, Fu WQ, Zheng XJ, et al. 2021 Avasimibe exerts anticancer effects on human glioblastoma cells via inducing cell apoptosis and cell cycle arrest. Acta Pharmacol. Sin. 42 97\u2013107","journal-title":"Acta Pharmacol. Sin."},{"key":"593_CR26","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","volume":"2","author":"JM Llovet","year":"2016","unstructured":"Llovet JM, Zucman-Rossi J, Pikarsky E, et al. 2016 Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 2 16018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"593_CR31","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1111\/j.1742-4658.2011.08271.x","volume":"278","author":"I Manov","year":"2011","unstructured":"Manov I, Pollak Y, Broneshter R, et al. 2011 Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib: The role of extracellular signal-regulated kinase counteraction. FEBS J. 278 3494\u20133507","journal-title":"FEBS J."},{"key":"593_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40170-023-00315-1","volume":"11","author":"SS Mayengbam","year":"2023","unstructured":"Mayengbam SS, Singh A, Yaduvanshi H, et al. 2023 Cholesterol reprograms glucose and lipid metabolism to promote proliferation in colon cancer cells. Cancer Metab. 11 15","journal-title":"Cancer Metab."},{"key":"593_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/1476-4598-13-204","volume":"13","author":"N Mohammad","year":"2014","unstructured":"Mohammad N, Malvi P, Meena A, et al. 2014 Cholesterol depletion by methyl-\u03b2-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma. Mol. Cancer 13 204","journal-title":"Mol. Cancer"},{"key":"593_CR33","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1158\/0008-5472.CAN-07-6161","volume":"68","author":"J Montero","year":"2008","unstructured":"Montero J, Morales A, Llacuna L, et al. 2008 Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 68 5246\u20135256","journal-title":"Cancer Res."},{"key":"593_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1158\/1535-7163.MCT-10-0544","volume":"10","author":"T Nagai","year":"2011","unstructured":"Nagai T, Arao T, Furuta K, et al. 2011 Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol. Cancer Ther. 10 169\u2013177","journal-title":"Mol. Cancer Ther."},{"key":"593_CR34","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/bjc.2017.77","volume":"116","author":"S Naito","year":"2017","unstructured":"Naito S, Makhov P, Astsaturov I, et al. 2017 LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma. Br. J. Cancer 116 1203\u20131207","journal-title":"Br. J. Cancer"},{"key":"593_CR36","doi-asserted-by":"crossref","unstructured":"Oldoni F, Sinke RJ and Kuivenhoven JA 2014 Mendelian disorders of high-density lipoprotein metabolism. Circ. Res. 114 124\u2013142","DOI":"10.1161\/CIRCRESAHA.113.300634"},{"key":"593_CR37","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2174\/1389557511313080007","volume":"13","author":"P Pal","year":"2013","unstructured":"Pal P, Gandhi H, Giridhar R, et al. 2013 ACAT inhibitors: The search for novel cholesterol lowering agents. Mini-Rev. Med. Chem. 13 1195\u20131219","journal-title":"Mini-Rev. Med. Chem."},{"key":"593_CR39","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.ajpath.2014.03.006","volume":"184","author":"K Pelton","year":"2014","unstructured":"Pelton K, Coticchia CM, Curatolo AS, et al. 2014 Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am. J. Pathol. 184 2099\u20132110","journal-title":"Am. J. Pathol."},{"key":"593_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/molecules23081941","volume":"23","author":"T Petan","year":"2018","unstructured":"Petan T, Jarc E and Jusovic M 2018 Lipid droplets in cancer: Guardians of fat in a stressful world. Molecules 23 11\u201315","journal-title":"Molecules"},{"key":"593_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/000313481408000230","volume":"80","author":"Q Qu","year":"2014","unstructured":"Qu Q, Wang S, Chen S, et al. 2014 Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma. Am. Surg. 80 191\u2013196","journal-title":"Am. Surg."},{"key":"593_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.atherosclerosis.2003.07.011","volume":"171","author":"FJ Raal","year":"2003","unstructured":"Raal FJ, Marais AD, Klepack E, et al. 2003 Avasimibe, an ACAT inhibitor, enhances the lipid-lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis 171 273\u2013279","journal-title":"Atherosclerosis"},{"key":"593_CR43","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1128\/MCB.01080-06","volume":"27","author":"M Rahmani","year":"2007","unstructured":"Rahmani M, Davis EM, Crabtree TR, et al. 2007 The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol. Cell. Biol. 27 5499\u20135513","journal-title":"Mol. Cell. Biol."},{"key":"593_CR42","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s10620-016-4085-6","volume":"61","author":"HL Reeves","year":"2016","unstructured":"Reeves HL, Zaki MYW and Day CP 2016 Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. Dig. Dis. Sci. 61 1234\u20131245","journal-title":"Dig. Dis. Sci."},{"key":"593_CR45","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1194\/jlr.D073197","volume":"58","author":"JG Schnitzler","year":"2017","unstructured":"Schnitzler JG, Bernelot Moens SJ, Tiessens F, et al. 2017 Nile Red Quantifier: A novel and quantitative tool to study lipid accumulation in patient-derived circulating monocytes using confocal microscopy. J. Lipid Res. 58 2210\u20132219","journal-title":"J. Lipid Res."},{"key":"593_CR47","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.4161\/auto.7.10.16818","volume":"7","author":"YH Shi","year":"2011","unstructured":"Shi YH, Ding Z, Zhou J, et al. 2011 Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 7 1159\u20131172","journal-title":"Autophagy"},{"key":"593_CR44","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. 2021 Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 209\u2013249","journal-title":"CA Cancer J. Clin."},{"key":"593_CR48","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1158\/0008-5472.CAN-16-1916","volume":"77","author":"G Tie","year":"2017","unstructured":"Tie G, Yan J, Khair L, et al. 2017 Hypercholesterolemia increases colorectal cancer incidence by reducing production of NKT and \u03b3\u03b4 T cells from hematopoietic stem cells. Cancer Res. 77 2351\u20132362","journal-title":"Cancer Res."},{"key":"593_CR51","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jhep.2018.07.004","volume":"69","author":"C Wang","year":"2018","unstructured":"Wang C, Jin H, Gao D, et al. 2018 Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J. Hepatol. 69 1057\u20131065","journal-title":"J. Hepatol."},{"key":"593_CR50","first-page":"16","volume":"7","author":"R Wong","year":"2011","unstructured":"Wong R and Frenette C 2011 Updates in the management of hepatocellular carcinoma. Gastroenterol. Hepatol. 7 16\u201324","journal-title":"Gastroenterol. Hepatol."},{"key":"593_CR52","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s12935-021-02175-5","volume":"21","author":"K Xiong","year":"2021","unstructured":"Xiong K, Wang G, Peng T, et al. 2021 The cholesterol esterification inhibitor avasimibe suppresses tumour proliferation and metastasis via the E2F\u20131 signalling pathway in prostate cancer. Cancer Cell Int. 21 461","journal-title":"Cancer Cell Int."},{"key":"593_CR53","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature17412","volume":"531","author":"W Yang","year":"2016","unstructured":"Yang W, Bai Y, Xiong Y, et al. 2016 Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature 531 651\u2013655","journal-title":"Nature"},{"key":"593_CR54","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3892\/ol.2017.5557","volume":"13","author":"S Yang","year":"2017","unstructured":"Yang S and Liu G 2017 Targeting the RAS\/RAF\/MEK\/ERK pathway in hepatocellular carcinoma. Oncol. Lett. 13 1041\u20131047","journal-title":"Oncol. Lett."},{"key":"593_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1741-7015-7-41","volume":"7","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Zhou X, Shen H, et al. 2009 Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 7 41","journal-title":"BMC Med."},{"key":"593_CR55","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1194\/jlr.M081745","volume":"59","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Chen CY, Li J, et al. 2018 In vitro exploration of ACAT contributions to lipid droplet formation during adipogenesis. J. Lipid Res. 59 820\u2013829","journal-title":"J. Lipid Res."}],"container-title":["Journal of Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12038-026-00593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12038-026-00593-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12038-026-00593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:03:05Z","timestamp":1778860985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12038-026-00593-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1007\/s12038-026-00593-z","relation":{},"ISSN":["0973-7138"],"issn-type":[{"value":"0973-7138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The findings reported in this study have been included in the patent application, A Novel Anti-Cancer Combination (Indian Patent Application Number: 202217060770, dated 25\n                      th\n                      October 2022) by Dipti Athavale, Manoj Kumar Bhat, Firoz Khan Bhati, and Himanshi Yaduvanshi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"26"}}